Is Foundayo an oral form of Wegovy?

No. Foundayo contains orforglipron and Wegovy contains semaglutide - different molecules under different approvals. They share the drug class and the approved use, not the ingredient.

Can Foundayo and Wegovy be taken together?

Both labels state that use with another GLP-1 receptor agonist is not recommended, which covers this combination.

Weight lossTwo labels compared

Foundayo vs Wegovy

Foundayo and Wegovy hold the closest pair of approvals in this category: both are GLP-1 receptor agonists approved for chronic weight management. One is a once-daily tablet of orforglipron, the other a once-weekly injection of semaglutide, and their labels diverge in reach: Wegovy covers cardiovascular risk and patients from age 12, Foundayo covers adults. This page compares the two documents.

Foundayo

Ingredient: Orforglipron
Approved for: Weight managementcovers weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $20.65 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter

Eli Lilly and Company. Label version 10, effective 29 July 2026.

Wegovy

Ingredient: Semaglutide
Approved for: Weight management, and cardiovascular risk in heart diseasecovers weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $653.12 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

A-S Medication Solutions. Label version 6, effective 23 April 2024.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	FoundayoOrforglipron	WegovySemaglutide
Active ingredient	FoundayoOrforglipronGLP-1 receptor agonist	WegovySemaglutideGLP-1 receptor agonist
Approved for	FoundayoWeight management	WegovyWeight management, and cardiovascular risk in heart disease
Supplysame in both	FoundayoPrescription	WegovyPrescription
What pharmacies payAcquisition cost, not retail	Foundayo$20.65 per tablet, capsule or pen, brand	Wegovy$653.12 per milliliter, brand
Boxed warningsame in both	FoundayoWARNING: RISK OF THYROID C-CELL TUMORS	WegovyWARNING: RISK OF THYROID C-CELL TUMORS
What the FDA approved it for	Foundayo FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.	Wegovy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity; Adults with overweight in the presence of at least one weight-related comorbid condition. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
Forms and strengths	Foundayo FOUNDAYO tablets are available as orforglipron: 0.8 mg: pink round tablet debossed with "L" on one side and "G1" on the other side 2.5 mg: light yellow round tablet debossed with "L" on one side and "G2" on the other side 5.5 mg: grayish purple round tablet debossed with "L" on one side and "G3" on the other side 9 mg: pink modified oval tablet debossed with "Lilly" on one side and "G4" on the...	Wegovy 2.4 mg/0.75 mL Injection: pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg.
How the label says it is taken	Foundayo Take FOUNDAYO orally once daily, with or without food. Swallow tablets whole. Do not break, crush, or chew. Do not take more than one tablet per day. Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily. After at least 30 days on the 2.5 mg dosage, increase dosage to 5.5 mg once daily. Dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability.	Wegovy Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage. The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly. Important Monitoring and Administration Instructions
Most common adverse reactions	Foundayo Most common adverse reactions, reported in ≥5% of patients treated with FOUNDAYO, are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss.	Wegovy Most common adverse reactions (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis. most common adverse reactions leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) for WEGOVY and placebo, respectively.
Warnings and precautions	Foundayo Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including FOUNDAYO. Discontinue if pancreatitis is suspected. Severe Gastrointestinal Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. FOUNDAYO is not recommended in patients with severe gastroparesis. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If suspected, advise the patient to promptly seek medical attention and discontinue FOUNDAYO. Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression. Acute Gallbladder Disease: Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated. Pulmonary Aspiration During General Anesthesia and Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures.	Wegovy Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated. Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. Acute Kidney Injury: Has occurred. Monitor renal function when initiating or escalating doses of WEGOVY in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions. Hypersensitivity Reactions: Anaphylactic reactions and angioedema have been reported postmarketing. Discontinue WEGOVY if suspected and promptly seek medical advice. Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has been reported in trials with semaglutide. Patients with a history of diabetic retinopathy should be monitored. Heart Rate Increase: Monitor heart rate at regular intervals. Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue WEGOVY if symptoms develop. Risk of Thyroid C-Cell Tumors In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures.
Contraindications	Foundayo FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2. Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. Personal or family history of MTC or in patients with MEN 2	Wegovy Personal or family history of MTC or in patients with MEN 2. Known hypersensitivity to semaglutide or any of the excipients in WEGOVY.
Drug interactions	Foundayo Strong CYP3A4 Inhibitors: The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 inhibitors that also inhibit OATP1B. CYP3A4 Inducers: Avoid concomitant use with strong CYP3A4 inducers. Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers. Simvastatin: Do not exceed simvastatin 20 mg once daily when used concomitantly with FOUNDAYO. FOUNDAYO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications.	Wegovy WEGOVY delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.
Label version	Foundayo29 July 2026	Wegovy23 April 2024

02Written by us

The shared ground: weight management as a GLP-1

Both labels cover reducing excess body weight and maintaining that reduction long term, in adults with obesity or with overweight plus at least one weight-related condition, in combination with a reduced-calorie diet and increased physical activity. Both describe GLP-1 receptor agonism and effects on appetite and caloric intake.

03Written by us

Where the documents part ways

Wegovy reaches further in two directions: its label adds reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and it covers pediatric patients aged 12 and older with obesity. The Foundayo label covers adults and carries no cardiovascular indication.

The route differs in kind: Foundayo is a tablet taken once daily with or without food; Wegovy is injected subcutaneously once weekly, with a maintenance dosage in adults of 2.4 mg or 1.7 mg.

04Written by us

The warnings read as one class

Both carry the boxed warning on thyroid C-cell tumors observed in rodents, with the contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2. Each label warns against combining its product with another GLP-1 receptor agonist, which rules out taking the two together.

05Written by us

What this page does not tell you

It does not rank the two products. They were approved on separate trial programs that were not designed to compare them, and reading trial numbers across the two labels as a ranking would misrepresent the evidence. The choice of treatment belongs to a prescriber.

06Written by us

Common questions

Is Foundayo an oral form of Wegovy?: No. Foundayo contains orforglipron and Wegovy contains semaglutide - different molecules under different approvals. They share the drug class and the approved use, not the ingredient.
Which one is approved for teenagers?: Wegovy: its label includes pediatric patients aged 12 and older with obesity. The Foundayo label covers adults.
Can Foundayo and Wegovy be taken together?: Both labels state that use with another GLP-1 receptor agonist is not recommended, which covers this combination.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Foundayo
Eli Lilly and Company. Label version 10, effective 29 July 2026.
Full label on DailyMed Approval record NDA220934
FDA prescribing information for Wegovy
A-S Medication Solutions. Label version 6, effective 23 April 2024.
Full label on DailyMed Approval record NDA215256

Each stripe is one section of the label, each division in a stripe one entry in that section. The red bar marks a boxed warning.

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.